Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
McKesson
Dow
Medtronic
Boehringer Ingelheim

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLOFARABINE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Clofarabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00028418 Clofarabine in Chronic Lymphocytic Leukemia Completed M.D. Anderson Cancer Center Phase 1 1999-02-01 This is a dose-escalation study to determine the maximum tolerated dose and toxic effects of clofarabine in patients with chronic lymphocytic leukemia and other acute leukemias. Clofarabine is a synthesized hybrid nucleoside analog, which is believed to possess the better qualities of fludarabine and chlorodeoxyadenosine, the 2 most active agents against lymphoproliferative disorders. Thus, it is hoped that this drug will be more active and less toxic than similar drugs.
NCT00042341 Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL) Completed Genzyme, a Sanofi Company Phase 2 2002-05-01 Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. The purpose of this study is to determine whether Clofarabine is safe and effective in the treatment of Acute Lymphoblastic Leukemia (ALL.)
NCT00042354 Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients Completed Genzyme, a Sanofi Company Phase 2 2002-05-01 Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. The purpose of this study is to determine whether Clofarabine is safe and effective in the treatment of Acute Myelogenous Leukemia (AML.)
NCT00044889 Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia Completed Genzyme, a Sanofi Company Phase 2 2002-05-01 Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This is a single arm, open-label, Phase II study of CLOFARABINE in adult patients with refractory or relapsed acute myelogenous leukemia (AML). Qualified patients must be refractory to one or two induction regimens, or have relapsed < one year from the date of confirmation of the initial complete remission (CR). There will be two phases in this study - an Induction phase and a Consolidation phase.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clofarabine

Condition Name

Condition Name for Clofarabine
Intervention Trials
Leukemia 41
Acute Myeloid Leukemia 30
Myelodysplastic Syndrome 22
Acute Lymphoblastic Leukemia 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Clofarabine
Intervention Trials
Leukemia 111
Leukemia, Myeloid, Acute 74
Leukemia, Myeloid 71
Preleukemia 49
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Clofarabine

Trials by Country

Trials by Country for Clofarabine
Location Trials
United States 458
Canada 20
France 9
United Kingdom 9
Italy 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Clofarabine
Location Trials
Texas 52
Tennessee 28
New York 25
California 24
Illinois 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Clofarabine

Clinical Trial Phase

Clinical Trial Phase for Clofarabine
Clinical Trial Phase Trials
Phase 3 7
Phase 2/Phase 3 4
Phase 2 74
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Clofarabine
Clinical Trial Phase Trials
Completed 73
Recruiting 30
Terminated 21
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Clofarabine

Sponsor Name

Sponsor Name for Clofarabine
Sponsor Trials
Genzyme, a Sanofi Company 60
National Cancer Institute (NCI) 30
M.D. Anderson Cancer Center 30
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Clofarabine
Sponsor Trials
Other 168
Industry 82
NIH 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Mallinckrodt
McKesson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.